NEW YORK, NY / ACCESSWIRE / February 20, 2019 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CVS Health Corporation("CVS" or the "Company") (NASDAQ: CVS). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/cvs.
The investigation concerns whether CVS and certain of its officers and/or directors have violated federal securities laws.
On February 20, 2019, CVS announced the Company's fourth quarter and full year financial and operating results and provided 2019 full year guidance. CVS advised investors that adjusted earnings in 2019 would be $6.68 to $6.88 per share, compared with the $7.36 average of market estimates, citing rising costs and poor results related to the Company's 2015 acquisition of Omnicare, Inc. Following this news, CVS's stock price fell sharply during intraday trading on February 20, 2019.
If you are aware of any facts relating to this investigation, or purchased CVS shares,you can assist this investigation by visiting the firm's site: www.bgandg.com/cvs. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | [email protected]
SOURCE: Bronstein, Gewirtz & Grossman, LLC